Evofem Biosciences (EVFM) Stock Price, News & Analysis

Company Overview

Evofem Biosciences is a clinical‐stage biotechnology company based in San Diego, California, specializing in women’s sexual and reproductive health. Founded in 2013 as a spin-out of the Scripps Research Institute, the company is focused on developing non-hormonal, on-demand products that address unmet needs in contraception and the prevention of sexually transmitted infections.

The company’s lead commercial product, Phexxi, is an FDA-approved, non-hormonal vaginal gel that maintains the vagina’s natural pH to reduce the risk of unintended pregnancy. Phexxi offers an alternative to hormonal birth control by using a proprietary combination of lactic acid, citric acid and potassium bitartrate. Beyond its marketed offering, Evofem maintains a research and development pipeline that includes additional vaginally administered candidates aimed at preventing chlamydia and gonorrhea, reflecting its commitment to broadening women’s health options.

Evofem Biosciences conducts its primary operations in the United States and engages with healthcare providers, payers and distribution partners to support product adoption and access. The company is led by a management team with experience in biotechnology commercialization and women’s health, and it continually explores strategic collaborations to advance its novel therapeutic platform and expand its geographic reach.

Key Stats

• Today's Range: $0.0106 to $0.0114
• 50-Day Range: $0.0089 to $0.0155
• 52-Week Range: $0.0061 to $0.0160
• Volume: 814,492 shs
• Average Volume: 462,429 shs
• Market Capitalization: $1.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Evofem Biosciences Stock Analysis - MarketRank™

Evofem Biosciences scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Evofem Biosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Evofem Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evofem Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the outstanding shares of Evofem Biosciences have been sold short.

Short Interest Ratio / Days to Cover

Evofem Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evofem Biosciences has recently decreased by 88.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evofem Biosciences does not currently pay a dividend.

Dividend Growth

Evofem Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.90

Percentage of Shares Shorted

0.01% of the outstanding shares of Evofem Biosciences have been sold short.

Short Interest Ratio / Days to Cover

Evofem Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evofem Biosciences has recently decreased by 88.54%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Evofem Biosciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Evofem Biosciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evofem Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.01% of the stock of Evofem Biosciences is held by insiders.

Percentage Held by Institutions

Only 0.22% of the stock of Evofem Biosciences is held by institutions.

EVFM Stock Analysis - Frequently Asked Questions

How have EVFM shares performed this year?

Evofem Biosciences' stock was trading at $0.0099 at the beginning of 2025. Since then, EVFM stock has increased by 11.1% and is now trading at $0.0110.

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences, Inc. (NASDAQ:EVFM) issued its earnings results on Friday, June, 16th. The biotechnology company reported ($1.85) earnings per share for the quarter, topping the consensus estimate of ($15.00) by $13.15. The biotechnology company earned $5.81 million during the quarter. Evofem Biosciences had a negative trailing twelve-month return on equity of 91.97% and a negative net margin of 46.42%.

When did Evofem Biosciences' stock split?

Shares of Evofem Biosciences reverse split on the morning of Thursday, May 18th 2023.The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Evofem Biosciences?

Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evofem Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), Plug Power (PLUG), Meta Platforms (META), Sorrento Therapeutics (SRNE), NVIDIA (NVDA) and Ford Motor (F).

Company Calendar

• Last Earnings: 6/16/2023
• Today: 10/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVFM
• CIK: 1618835
• Web: www.evofem.com
• Phone: (858) 550-1900
• Fax: 844-828-2010
• Employees: 120
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): ($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $52.98 million
• Net Margins: -46.42%
• Pretax Margin: -46.42%
• Return on Equity: -91.97%
• Return on Assets: -61.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.09

Sales & Book Value

• Annual Sales: $11.39 million
• Price / Sales: 0.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.64) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 126,686,000
• Free Float: 113,118,000
• Market Cap: $1.39 million
• Optionable: Not Optionable
• Beta: -1.13